- Home
- CR vs MRNA Comparison
CR vs MRNA Comparison
Compare CR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CR
- MRNA
- Stock Information
- Founded
- CR 1855
- MRNA 2010
- Country
- CR United States
- MRNA United States
- Employees
- CR 7300
- MRNA 5800
- Industry
- CR Metal Fabrications
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CR Industrials
- MRNA Health Care
- Exchange
- CR Nasdaq
- MRNA Nasdaq
- Market Cap
- CR 10.9B
- MRNA 9.2B
- IPO Year
- CR N/A
- MRNA 2018
- Fundamental
- Price
- CR $189.34
- MRNA $23.88
- Analyst Decision
- CR Strong Buy
- MRNA Hold
- Analyst Count
- CR 5
- MRNA 15
- Target Price
- CR $223.60
- MRNA $37.15
- AVG Volume (30 Days)
- CR 296.4K
- MRNA 11.9M
- Earning Date
- CR 10-27-2025
- MRNA 11-06-2025
- Dividend Yield
- CR 0.49%
- MRNA N/A
- EPS Growth
- CR 37.96
- MRNA N/A
- EPS
- CR 6.25
- MRNA N/A
- Revenue
- CR $2,268,100,000.00
- MRNA $2,232,000,000.00
- Revenue This Year
- CR $10.74
- MRNA N/A
- Revenue Next Year
- CR $10.97
- MRNA $10.38
- P/E Ratio
- CR $30.25
- MRNA N/A
- Revenue Growth
- CR 19.64
- MRNA N/A
- 52 Week Low
- CR $127.04
- MRNA $23.15
- 52 Week High
- CR $203.89
- MRNA $56.70
- Technical
- Relative Strength Index (RSI)
- CR 53.62
- MRNA 41.42
- Support Level
- CR $187.28
- MRNA $23.48
- Resistance Level
- CR $192.00
- MRNA $25.56
- Average True Range (ATR)
- CR 5.25
- MRNA 1.42
- MACD
- CR -0.07
- MRNA -0.35
- Stochastic Oscillator
- CR 26.80
- MRNA 8.19
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.